Marissa Brittenham Sells 8,785 Shares of Surgery Partners (NASDAQ:SGRY) Stock

Surgery Partners, Inc. (NASDAQ:SGRY) insider Marissa Brittenham sold 8,785 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $13.70, for a total transaction of $120,354.50. Following the completion of the sale, the insider owned 54,623 shares of the company’s stock, valued at $748,335.10. This trade represents a 13.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Surgery Partners Price Performance

Shares of NASDAQ SGRY opened at $12.95 on Wednesday. The company has a quick ratio of 1.71, a current ratio of 1.87 and a debt-to-equity ratio of 1.15. The business’s 50 day moving average price is $15.10 and its two-hundred day moving average price is $17.93. The company has a market cap of $1.68 billion, a PE ratio of -20.89 and a beta of 1.95. Surgery Partners, Inc. has a twelve month low of $12.25 and a twelve month high of $24.60.

Surgery Partners (NASDAQ:SGRY) last released its quarterly earnings data on Monday, March 2nd. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The business had revenue of $885.00 million during the quarter, compared to analyst estimates of $866.54 million. During the same period in the previous year, the business earned $0.44 earnings per share. The business’s quarterly revenue was up 2.4% on a year-over-year basis. On average, analysts predict that Surgery Partners, Inc. will post 0.67 EPS for the current year.

Surgery Partners announced that its board has authorized a share repurchase plan on Thursday, February 26th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 9.7% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Institutional Investors Weigh In On Surgery Partners

A number of large investors have recently added to or reduced their stakes in the stock. Jones Financial Companies Lllp increased its stake in Surgery Partners by 313.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,227 shares of the company’s stock worth $27,000 after acquiring an additional 930 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in shares of Surgery Partners by 45,640.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,287 shares of the company’s stock worth $49,000 after purchasing an additional 2,282 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Surgery Partners by 128.4% in the third quarter. PNC Financial Services Group Inc. now owns 2,702 shares of the company’s stock worth $58,000 after purchasing an additional 1,519 shares during the period. Aquatic Capital Management LLC bought a new position in shares of Surgery Partners in the third quarter worth $121,000. Finally, State of Alaska Department of Revenue acquired a new position in Surgery Partners in the third quarter valued at about $151,000.

More Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus remains constructive — several brokerages rate SGRY as a “Moderate Buy,” which supports baseline investor demand. Brokerage Recommendation
• Positive Sentiment: Investor conference access: Management presented at the Barclays 28th Annual Global Healthcare Conference (Mar 10), providing a forum to reiterate guidance and margin improvement plans — useful upside catalyst if commentary is clear and credible. Prepared Remarks Transcript
• Positive Sentiment: Short interest fell ~15.7% in February (still ~11% of float but lower than mid‑month), which reduces one source of bearish positioning and could limit further short-driven price pressure.
• Neutral Sentiment: Prepared remarks and Q4 write‑ups: Recent transcripts and industry Q4 summaries provide more detail on volumes and outpatient trends but contain no single new, market‑moving disclosure. Q4 Coverage
• Negative Sentiment: Activist pressure: Ortelius Capital is pushing for board changes and asset sales, increasing the chance of near‑term strategic disruption, management turnover or contentious proxy fights. Activist Story
• Negative Sentiment: Fraud probe announced: Law firm Levi & Korsinsky opened an investigation into prior management statements on margin expansion, raising potential legal/settlement risk and heightening investor uncertainty. Fraud Investigation
• Negative Sentiment: Significant insider selling: Multiple executives (CEO, CFO and other officers) sold sizable blocks the week of Mar 5–6 at roughly $13.60–$13.93, which the market often interprets negatively for near‑term confidence. Representative SEC filing: CEO Sale Filing
• Negative Sentiment: Recent earnings execution: The March 2 Q4 report showed a meaningful EPS miss (revenue slight beat but EPS well below street), highlighting execution/margin risk that underpins some of the legal and activist scrutiny.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Royal Bank Of Canada decreased their price objective on shares of Surgery Partners from $31.00 to $20.00 and set an “outperform” rating on the stock in a report on Wednesday, March 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Surgery Partners in a research note on Wednesday, March 4th. Barclays reduced their target price on shares of Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating for the company in a report on Tuesday, March 3rd. TD Cowen decreased their price target on shares of Surgery Partners from $28.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Surgery Partners in a research report on Wednesday, March 4th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.60.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.